A University of Alberta research team writing in The Conversation says the reason semaglutide produces very different results from one person to the next may come down to how individual bodies burn energy. The group is recruiting participants now for a six-month study using a rare measurement facility.
Semaglutide, sold as Ozempic and Wegovy, is a GLP-1 receptor agonist that helps regulate blood sugar, appetite and body weight. The authors describe it acting on the brain to increase fullness and decrease appetite, and note that research has shown GLP-1 medications reduce body weight by an average of 15 percent when used weekly for 68 weeks alongside lifestyle interventions.
Why an average hides the story
That 15 percent figure is an average, and averages are exactly where the interesting variation gets buried. The team says it is exploring whether individual responses trace back to genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age and sex.
Weight is also only one measure. The authors note research has shown semaglutide medications to improve quality of life, blood markers such as sugar or cholesterol, strength and overall health, which means a patient the scale calls a non-responder may not be one.
The dimming light bulb
The mechanism the group is most interested in is metabolic adaptation, also called adaptive thermogenesis. When we lose weight the body needs less energy, but sometimes it enters an extra energy-saving mode and burns even fewer calories than expected.
The authors compare it to a light bulb that automatically dims to save electricity, and offer it as one reason weight loss gets harder over time and plateaus appear. Both fat and fat-free mass use energy at rest, so losing either tissue lowers the baseline burn.
A room that measures calories
Alberta has a whole-room indirect calorimeter, described as a rare facility resembling a hotel suite that precisely measures each component of energy use at rest, after eating and during exercise. Participants with insulin resistance or diabetes who are about to start semaglutide will be followed for six months.
Limitations
No results exist yet: recruitment is ongoing and the study is prospective. The team's own published review of GLP-1 therapies and energy utilization found only a few studies on how semaglutide affects resting energy use, with findings the authors call neutral or inconclusive.
An open question, honestly labeled
The authors say how semaglutide impacts energy use is an emerging area and remains an open question. Their stated goal is anticipating non-responders earlier so alternatives can be offered sooner.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.